# Cystic Fibrosis Microbiome-determined Antibiotic Therapy Trial in Exacerbations: Results Stratified

> **NCT02526004** · NA · COMPLETED · sponsor: **University College Cork** · enrollment: 223 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** Ceftazidime
- **DRUG:** Tobramycin

## Key facts

- **NCT ID:** NCT02526004
- **Lead sponsor:** University College Cork
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10-01
- **Primary completion:** 2017-06-30
- **Final completion:** 2018-06-30
- **Target enrollment:** 223 (ACTUAL)
- **Last updated:** 2025-04-10

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02526004

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02526004, "Cystic Fibrosis Microbiome-determined Antibiotic Therapy Trial in Exacerbations: Results Stratified". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02526004. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*